SCHEMBL21823766

SCHEMBL21823766

N#Cc1c(-c2csc(-c3ccco3)n2)oc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 9/20 0.44
▸ MAPT P10636 9/20 0.44
▸ ALDH1A1 P00352 7/20 0.44
▸ KDM4E B2RXH2 7/20 0.44
▸ PKM P14618 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ KDM4C Q9H3R0 1/20 0.44
▸ CYP19A1 P11511 1/20 0.43
▸ ADORA2A P29274 8/20 0.43
▸ ADORA1 P30542 8/20 0.43
▸ ADORA2B P29275 7/20 0.43
▸ MEN1 O00255 8/20 0.43
▸ KMT2A Q03164 8/20 0.43
▸ HPGD P15428 5/20 0.43
▸ ALOX15 P16050 5/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 4/20 0.38
▸ USP2 O75604 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21823778 0.82 MAPT (0.47) HSD17B10MAPTALDH1A1KDM4EPKM
SCHEMBL7253210 0.73 CYP19A1 (0.72) HSD17B10MAPTALDH1A1KDM4EPKM
SCHEMBL21824293 0.73 MAPT (0.50) HSD17B10MAPTALDH1A1KDM4EPKM
SCHEMBL28051569 0.68 ALDH1A1 (0.50) HSD17B10MAPTALDH1A1KDM4EPKM
SCHEMBL2105545 0.66 CYP19A1 (0.54) HSD17B10MAPTALDH1A1KDM4EPKM
SCHEMBL21823805 0.66 ALDH1A1 (0.58) HSD17B10MAPTALDH1A1KDM4EPKM
SCHEMBL16767195 0.65 MAPT (0.65) HSD17B10MAPTALDH1A1KDM4EPKM
SCHEMBL17336534 0.64 ALDH1A1 (0.56) HSD17B10MAPTALDH1A1KDM4EPKM
SCHEMBL21823785 0.64 CYP19A1 (0.47) HSD17B10MAPTALDH1A1KDM4EPKM
SCHEMBL21823773 0.64 CYP19A1 (0.47) HSD17B10MAPTALDH1A1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3860994-B1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE UNIV BRITISH COLUMBIA (CA) 2024-08-14 — — EP disclosed
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2022-04-07 — — US disclosed
EP-3860994-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE The University of British Columbia (CA) 2021-08-11 — — EP disclosed
WO-2020069625-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2020-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use BRDT, CBFB, CREBBP HSD17B10 3800/4885MAPT 1816/4885ALDH1A1 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback